Home | Business News | Browse by Publication | B | Biotech Business

NON-BRAIN PENETRANT CB1 ANTAGONISTS CAN TREAT DIABETES/OBESITY.

Publication: Biotech Business
Publication Date: 01-DEC-08
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Research shows that proprietary non-brain penetrant cannabinoid subtype 1 (CB1) receptor antagonists developed by Jenrin Discovery are able to produce metabolically favorable effects in peripheral tissues, including fat and liver. The research also showed for the first time that these results are achievable when CB1 antagonists are modified so that they do not cross the blood-brain barrier, thereby reducing the risk of psychiatric side effects associated with the use of CB1 antagonists that are brain-penetrant. Results were presented in a plenary...

Access Full Article, Compliments of Goliath

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Biotech Business
TOVAXIN REDUCES DISABILITY FOR MULTIPLE SCELEROSIS.(Clinical report), December 01, 2008
ORASURE SUBMITS ORAQUICK HCV TEST PMA TO FDA., December 01, 2008
ROCKWELL MEDICAL ANNOUNCES UPDATED DSMB RESULTS.(Financial report), December 01, 2008

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.